Mpex Pharmaceuticals, Inc.

San Diego, CA 92109
10 Employees

SBIR Award Summary

Total Number of Awards 3
Total Value of Awards $486K
First Award Date 04/15/04
Most Recent Award Date 06/06/05

Key Personnel

Last Name Name Awards Contact
Lomovskaya Dr. Olga Lomovskaya 2 Message
Surber Mark W Surber 1

3 Awards Won

Phase 1 SBIR

Agency: Office of the Secretary of Defense
Topic: OSD04-H19
Budget: 06/06/05 - 06/06/06

Fluoroquinolones (FQs) are among the limited arsenal of antibiotics available to treat highly intrinsic-resistant Gram-negative bacteria, such as Acinetobacter and Pseudomonas, which are considered to be among the most difficult hospital-acquired infections to treat and control. Over the last decade antibiotic efflux due to the activity of multi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Budget: 01/01/05 - 06/30/05

DESCRIPTION (provided by applicant): The recent clinical implication of efflux pump mechanisms in multi-drug resistance (MDR) warrants the identification and development of efficacious and safe agents capable of blocking efflux activity. Recent solving of the E. coli AcrB 3D structure has opened a unique opportunity to apply structural methods t...

Phase 1 SBIR

Agency: Department of Health & Human Services
Budget: 04/15/04 - 03/31/05

DESCRIPTION (provided by applicant): The recent threat of bioterrorism has intensified the need for new classes of antibiotics. Among biodefense category A bacterial pathogens, many species are currently susceptible to existing antibiotics. However, the development of bioweapon strains of Bacillus anthracis and Yersinia pestis that are resistant...